Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma

doi:10.4251/wjgo.v17.i7.103337

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (404)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

HTML

240

Figures (1-5)

Tables (1-4)

Sum=360

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=16

Jul 15, 2025 (publication date) through Jul 28, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Jul 15, 2025; 17(7): 103337
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.103337

Table 3 Previous phase II/III clinical trials of third-line therapeutic options for pancreatic cancer

Clinical trial identifier	Year	Patients	Study phase	Tumor stage	Treatment regimes	Median OS (months)	Median FPS (months)	Ref.
NAPOLI-1	2019	86	Retrospective	mPDAC	Nanoliposomal irinotecan + 5-fluorouracil and leucovorin	9.4	3.5	[77]
NAPOLI-1NCT01494506	2020	417	Phase III	mPDAC	Nanoliposomal irinotecan + 5-fluorouracil/leucovorin	5.8 vs 4.3	2.8 vs 1.4	[78]
NR	2023	29	Phase II/III	LA-mPC	Nanoliposomal irinotecan plus 5-fluorouracil/leucovorin	10.27 vs 9.33	2.90 vs 3.60	[80]

OS: Overall survival; PFS: Progression-free survival; mPDAC: Metastatic pancreatic ductal adenocarcinoma; LA-mPC: Locally advanced metastatic pancreatic cancer.

Citation: Hendi M, Zhang B, Mou YP, Cai XJ. Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2025; 17(7): 103337
URL: https://www.wjgnet.com/1948-5204/full/v17/i7/103337.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i7.103337